Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Acquired by John G Ullman & Associates Inc.

John G Ullman & Associates Inc. increased its stake in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Free Report) by 14.6% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 30,150 shares of the medical equipment provider's stock after acquiring an additional 3,850 shares during the quarter. John G Ullman & Associates Inc.'s holdings in Zimmer Biomet were worth $3,412,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Garde Capital Inc. purchased a new position in shares of Zimmer Biomet during the first quarter valued at approximately $29,000. Menard Financial Group LLC bought a new position in Zimmer Biomet during the 4th quarter valued at approximately $30,000. Washington Trust Advisors Inc. purchased a new position in Zimmer Biomet during the first quarter valued at $30,000. Columbia River Financial Group LLC purchased a new stake in shares of Zimmer Biomet in the first quarter worth $30,000. Finally, Accredited Wealth Management LLC bought a new position in shares of Zimmer Biomet during the fourth quarter valued at $36,000. 88.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

ZBH has been the subject of a number of analyst reports. Royal Bank Of Canada reduced their price objective on shares of Zimmer Biomet from $125.00 to $112.00 and set an "outperform" rating for the company in a research note on Tuesday, May 6th. The Goldman Sachs Group decreased their price objective on shares of Zimmer Biomet from $120.00 to $104.00 and set a "neutral" rating for the company in a report on Tuesday, May 6th. Evercore ISI decreased their price target on Zimmer Biomet from $102.00 to $96.00 and set an "in-line" rating for the company in a research note on Tuesday, July 8th. Roth Capital upgraded Zimmer Biomet from a "neutral" rating to a "buy" rating and set a $135.00 price objective for the company in a report on Tuesday, July 15th. Finally, Wells Fargo & Company lowered their target price on shares of Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Tuesday, May 6th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $111.39.

Insider Activity at Zimmer Biomet

In other news, insider Sang Yi sold 1,000 shares of Zimmer Biomet stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $95.00, for a total transaction of $95,000.00. Following the completion of the sale, the insider directly owned 20,424 shares in the company, valued at approximately $1,940,280. This trade represents a 4.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.39% of the company's stock.

Zimmer Biomet Price Performance

ZBH traded up $0.72 on Friday, hitting $97.59. 1,068,261 shares of the company's stock traded hands, compared to its average volume of 1,849,641. Zimmer Biomet Holdings, Inc. has a one year low of $89.22 and a one year high of $116.71. The company has a current ratio of 2.44, a quick ratio of 1.46 and a debt-to-equity ratio of 0.53. The firm has a market cap of $19.31 billion, a price-to-earnings ratio of 21.59, a P/E/G ratio of 2.26 and a beta of 0.71. The company's 50 day simple moving average is $93.20 and its 200-day simple moving average is $100.64.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last posted its earnings results on Monday, May 5th. The medical equipment provider reported $1.81 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a net margin of 11.86% and a return on equity of 12.73%. The company had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same period last year, the company posted $1.94 earnings per share. Zimmer Biomet's quarterly revenue was up 1.1% on a year-over-year basis. As a group, research analysts anticipate that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Thursday, July 31st. Shareholders of record on Thursday, June 26th will be given a dividend of $0.24 per share. The ex-dividend date is Thursday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 0.98%. Zimmer Biomet's dividend payout ratio (DPR) is presently 21.24%.

Zimmer Biomet Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.